Wednesday, May 26, 2010 6:53:49 PM
Let's clear the air:
Eva Harris will be having lunch with Seymour that Sunday. She happens to be in LA then for a conference. We don't know what kind of conference or what, if anything, she will be doing at it. It could be business related, it could be something else entirely. We just don't know.
That's it, no more, no less. Anything beyond that is pure speculation.
I suspect that the speculation is fueled by a desire to see some results from the Dengue tests. To suggest that Seymour is dropping hints is ludicrous. To suggest Harris will be presenting Dengue results on a Sunday in Los Angeles is equally untenable.
Eva Harris will be having lunch with Seymour that Sunday. She happens to be in LA then for a conference. We don't know what kind of conference or what, if anything, she will be doing at it. It could be business related, it could be something else entirely. We just don't know.
That's it, no more, no less. Anything beyond that is pure speculation.
I suspect that the speculation is fueled by a desire to see some results from the Dengue tests. To suggest that Seymour is dropping hints is ludicrous. To suggest Harris will be presenting Dengue results on a Sunday in Los Angeles is equally untenable.
Recent NNVC News
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
